CSF tau microtubule-binding region identifies pathological changes in primary tauopathies
© 2022. The Author(s)..
Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using immunoprecipitation and mass spectrometry, we show that 4 repeat (4R) isoform-specific tau species from microtubule-binding region (MTBR-tau275 and MTBR-tau282) increase in the brains of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD)-MAPT and AD but decrease inversely in the cerebrospinal fluid (CSF) of CBD, FTLD-MAPT and AD compared to control and other FTLD-tau (for example, Pick's disease). CSF MTBR-tau measures are reproducible in repeated lumbar punctures and can be used to distinguish CBD from control (receiver operating characteristic area under the curve (AUC) = 0.889) and other FTLD-tau, such as PSP (AUC = 0.886). CSF MTBR-tau275 and MTBR-tau282 may represent the first affirmative biomarkers to aid in the diagnosis of primary tauopathies and facilitate clinical trial designs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Nature medicine - 28(2022), 12 vom: 24. Dez., Seite 2547-2554 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Horie, Kanta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 02.01.2023 Date Revised 28.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41591-022-02075-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349375224 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349375224 | ||
| 003 | DE-627 | ||
| 005 | 20240229165957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41591-022-02075-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1310.xml |
| 035 | |a (DE-627)NLM349375224 | ||
| 035 | |a (NLM)36424467 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Horie, Kanta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CSF tau microtubule-binding region identifies pathological changes in primary tauopathies |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.01.2023 | ||
| 500 | |a Date Revised 28.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Despite recent advances in fluid biomarker research in Alzheimer's disease (AD), there are no fluid biomarkers or imaging tracers with utility for diagnosis and/or theragnosis available for other tauopathies. Using immunoprecipitation and mass spectrometry, we show that 4 repeat (4R) isoform-specific tau species from microtubule-binding region (MTBR-tau275 and MTBR-tau282) increase in the brains of corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal lobar degeneration (FTLD)-MAPT and AD but decrease inversely in the cerebrospinal fluid (CSF) of CBD, FTLD-MAPT and AD compared to control and other FTLD-tau (for example, Pick's disease). CSF MTBR-tau measures are reproducible in repeated lumbar punctures and can be used to distinguish CBD from control (receiver operating characteristic area under the curve (AUC) = 0.889) and other FTLD-tau, such as PSP (AUC = 0.886). CSF MTBR-tau275 and MTBR-tau282 may represent the first affirmative biomarkers to aid in the diagnosis of primary tauopathies and facilitate clinical trial designs | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Barthélemy, Nicolas R |e verfasserin |4 aut | |
| 700 | 1 | |a Spina, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a VandeVrede, Lawren |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yingxin |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Ross W |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Brenton A |e verfasserin |4 aut | |
| 700 | 1 | |a Day, Gregory S |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Albert A |e verfasserin |4 aut | |
| 700 | 1 | |a Karch, Celeste M |e verfasserin |4 aut | |
| 700 | 1 | |a Seeley, William W |e verfasserin |4 aut | |
| 700 | 1 | |a Perrin, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Koppisetti, Rama K |e verfasserin |4 aut | |
| 700 | 1 | |a Shaikh, Faris |e verfasserin |4 aut | |
| 700 | 1 | |a Lago, Argentina Lario |e verfasserin |4 aut | |
| 700 | 1 | |a Heuer, Hilary W |e verfasserin |4 aut | |
| 700 | 1 | |a Ghoshal, Nupur |e verfasserin |4 aut | |
| 700 | 1 | |a Gabelle, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Bruce L |e verfasserin |4 aut | |
| 700 | 1 | |a Boxer, Adam L |e verfasserin |4 aut | |
| 700 | 1 | |a Bateman, Randall J |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Chihiro |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature medicine |d 1995 |g 28(2022), 12 vom: 24. Dez., Seite 2547-2554 |w (DE-627)NLM074659804 |x 1546-170X |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2022 |g number:12 |g day:24 |g month:12 |g pages:2547-2554 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41591-022-02075-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2022 |e 12 |b 24 |c 12 |h 2547-2554 | ||